



F-star Therapeutics to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference

Cambridge, UK and Cambridge, MA, September XX, 2020 – F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb^{2™}) antibodies, today announces that Eliot Forster, Chief Executive Officer, will be presenting at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020.

Event: F-star Therapeutics Presentation

Time: 3:30 PM ET | 8:30 PM BST

Webcast Link: F-star Therapeutics Presentation <https://hcwevents.com>

The Company will also be available for one to one meetings during the conference, September 14-16.

- END-

About F-star Therapeutics Ltd

F-star is a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immunology treatments. Through its proprietary tetravalent, bispecific antibody (mAb^{2™}) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com.

For further information, please contact:

For investor enquiries

Lindsey Trickett

VP Investor Relations & Communications

+1 240 543 7970

lindsey.trickett@f-star.com

For media enquiries

Consilium Strategic Communications

Chris Gardner, Sue Stuart, David Daley

Tel: +44 (0)20 3709 5700

E-mail: F-star@consilium-comms.com